XBiotech Inc. (NASDAQ:XBIT - Get Free Report)'s stock price passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $3.10 and traded as low as $2.84. XBiotech shares last traded at $2.88, with a volume of 38,981 shares changing hands.
XBiotech Price Performance
The firm's fifty day moving average is $3.09 and its two-hundred day moving average is $4.23. The firm has a market capitalization of $89.97 million, a PE ratio of -2.74 and a beta of 0.98.
XBiotech (NASDAQ:XBIT - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter.
Hedge Funds Weigh In On XBiotech
Several hedge funds have recently made changes to their positions in the stock. Hsbc Holdings PLC bought a new stake in XBiotech during the 1st quarter valued at approximately $52,000. JPMorgan Chase & Co. raised its holdings in shares of XBiotech by 68.2% in the fourth quarter. JPMorgan Chase & Co. now owns 14,624 shares of the biopharmaceutical company's stock worth $58,000 after buying an additional 5,930 shares during the period. Virtu Financial LLC purchased a new stake in shares of XBiotech in the 4th quarter worth approximately $58,000. Bank of America Corp DE increased its holdings in shares of XBiotech by 42.0% during the fourth quarter. Bank of America Corp DE now owns 19,888 shares of the biopharmaceutical company's stock valued at $79,000 after acquiring an additional 5,887 shares in the last quarter. Finally, Nuveen LLC purchased a new position in XBiotech during the first quarter valued at approximately $81,000. 55.70% of the stock is currently owned by hedge funds and other institutional investors.
XBiotech Company Profile
(
Get Free Report)
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
Read More
Before you consider XBiotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.
While XBiotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
